Dynamic changes of circulating tumour DNA in surgical lung cancer patients: protocol for a prospective observational study

Kezhong Chen, Heng Zhao, Fan Yang, Bengang Hui, Tianyang Wang, Lieu Tu Wang, Yanbin Shi, Jun Wang, Kezhong Chen, Heng Zhao, Fan Yang, Bengang Hui, Tianyang Wang, Lieu Tu Wang, Yanbin Shi, Jun Wang

Abstract

Introduction: Circulating tumour DNA (ctDNA) has potential applications in cancer management. Most previous studies about ctDNA focused on advanced stage cancer patients. We have completed a clinical prospective study (NCT02645318) and showed the feasibility and clinical application of ctDNA detection in early stage non-small cell lung cancer (NSCLC) patients. The aim of this study is to investigate the elimination rate of ctDNA level after surgery. This is the first prospective study to evaluate the perioperative dynamic changes of ctDNA in surgical lung cancer patients.

Methods and analysis: This is a prospective observational study to determine the elimination rate of circulating tumour DNA after surgery. Consecutive patients with suspected lung cancer who undergo curative-intent lung resection will be enrolled. 10 mL blood samples are taken by intravenous puncture. Plasma samples are obtained before surgery (time A) and at a series of scheduled time-points (2 min to 72 hours, time B to F) after tumour resection. DNA is prepared from 4 mL of purified plasma. A multiplex assay based on circulating single-molecule amplification and resequencing technology (cSMART) is used to simultaneously detect and quantitate hot spot EGFR, KRAS, BRAF, ERBB2, PIK3CA, TP53, ALK, RET and MET plasma DNA variants. Positive plasma mutations are validated in tumour tissue and normal lung tissue by targeted sequencing.

Ethics and dissemination: Ethical approval has been obtained from the Peking University People's Hospital Medical Ethics Committee (2016PHB156-01). Results will be disseminated through presentations at scientific meetings and publications in peer-reviewed journals.

Trial registration number: NCT02965391; Pre-results.

Keywords: oncogenes; respiratory tract tumours; thoracic surgery.

Conflict of interest statement

Competing interests: None declared.

© Article author(s) (or their employer(s) unless otherwise stated in the text of the article) 2018. All rights reserved. No commercial use is permitted unless otherwise expressly granted.

Figures

Figure 1
Figure 1
Flow diagram.
Figure 2
Figure 2
Concept of cSMART for quantification of allelic variants in plasma.

References

    1. Wan JCM, Massie C, Garcia-Corbacho J, et al. . Liquid biopsies come of age: towards implementation of circulating tumour DNA. Nat Rev Cancer 2017;17:223–38. 10.1038/nrc.2017.7
    1. Mok T, Wu YL, Lee JS, et al. . Detection and dynamic changes of EGFR mutations from circulating tumor DNA as a predictor of survival outcomes in NSCLC patients treated with first-line intercalated erlotinib and chemotherapy. Clin Cancer Res 2015;21:3196–203. 10.1158/1078-0432.CCR-14-2594
    1. Rosell R, Karachaliou N. Lung cancer: using ctDNA to track EGFR and KRAS mutations in advanced-stage disease. Nat Rev Clin Oncol 2016;13:401–2. 10.1038/nrclinonc.2016.83
    1. Mao X, Zhang Z, Zheng X, et al. . Capture-based targeted ultradeep sequencing in paired tissue and plasma samples demonstrates differential subclonal ctDNA-releasing capability in advanced lung cancer. J Thorac Oncol 2017;12:663–72. 10.1016/j.jtho.2016.11.2235
    1. Newman AM, Bratman SV, To J, et al. . An ultrasensitive method for quantitating circulating tumor DNA with broad patient coverage. Nat Med 2014;20:548–54. 10.1038/nm.3519
    1. Garcia-Murillas I, Schiavon G, Weigelt B, et al. . Mutation tracking in circulating tumor DNA predicts relapse in early breast cancer. Sci Transl Med 2015;7:302ra133 10.1126/scitranslmed.aab0021
    1. Lo YM, Zhang J, Leung TN, et al. . Rapid clearance of fetal DNA from maternal plasma. Am J Hum Genet 1999;64:218–24. 10.1086/302205
    1. Diehl F, Schmidt K, Choti MA, et al. . Circulating mutant DNA to assess tumor dynamics. Nat Med 2008;14:985–90. 10.1038/nm.1789
    1. Heitzer E, Ulz P, Geigl JB. Circulating tumor DNA as a liquid biopsy for cancer. Clin Chem 2015;61:112–23. 10.1373/clinchem.2014.222679
    1. Vansteenkiste J, Crinò L, Dooms C, et al. . 2nd ESMO consensus conference on lung cancer: early-stage non-small-cell lung cancer consensus on diagnosis, treatment and follow-up. Ann Oncol 2014;25:1462–74. 10.1093/annonc/mdu089
    1. Xie Y, Minna JD. A lung cancer molecular prognostic test ready for prime time. Lancet 2012;379:785–7. 10.1016/S0140-6736(12)60154-8
    1. Tie J, Wang Y, Tomasetti C, et al. . Circulating tumor DNA analysis detects minimal residual disease and predicts recurrence in patients with stage II colon cancer. Sci Transl Med 2016;8:346ra92 10.1126/scitranslmed.aaf6219
    1. Chen K, Zhang J, Guan T, et al. . Comparison of plasma to tissue DNA mutations in surgical patients with non-small cell lung cancer. J Thorac Cardiovasc Surg 2017;154:1123–31. 10.1016/j.jtcvs.2017.04.073
    1. Wang Z, Cheng G, Han X, et al. . Application of single-molecule amplification and resequencing technology for broad surveillance of plasma mutations in patients with advanced lung adenocarcinoma. J Mol Diagn 2017;19:169–81. 10.1016/j.jmoldx.2016.09.008
    1. Lv W, Wei X, Guo R, et al. . Noninvasive prenatal testing for Wilson disease by use of circulating single-molecule amplification and resequencing technology (cSMART). Clin Chem 2015;61:172–81. 10.1373/clinchem.2014.229328
    1. An SJ, Chen ZH, Su J, et al. . Identification of enriched driver gene alterations in subgroups of non-small cell lung cancer patients based on histology and smoking status. PLoS One 2012;7:e40109 10.1371/journal.pone.0040109
    1. Shi Y, Au JS, Thongprasert S, et al. . A prospective, molecular epidemiology study of EGFR mutations in Asian patients with advanced non-small-cell lung cancer of adenocarcinoma histology (PIONEER). J Thorac Oncol 2014;9:154–62. 10.1097/JTO.0000000000000033
    1. Chen KZ, Lou F, Yang F, et al. . Circulating Tumor DNA detection in early-stage non-small cell lung cancer patients by targeted sequencing. Sci Rep 2016;6:31985 10.1038/srep31985
    1. To EW, Chan KC, Leung SF, et al. . Rapid clearance of plasma Epstein-Barr virus DNA after surgical treatment of nasopharyngeal carcinoma. Clin Cancer Res 2003;9:3254–9.

Source: PubMed

赞助者和合作者

医疗条件

药物干预

3
订阅